healthcare

healthcare Articles

PetMed shares retreated after it reported disappointing fiscal first-quarter financial results before the markets opened on Monday.
"Inaccurate or delayed diagnoses are the most catastrophic and costly of medical errors and will affect most of us in our lifetimes." So says the Society to Improve Diagnosis in Medicine.
For those with a long-term horizon, now may be a good time to buy some shares in cannabis stocks, put them in your account and be patient. Merrill Lynch has five pot stocks rated Buy, and all have...
Johnson & Johnson shares took a hit after earnings, but it was more than just the earnings and guidance to blame. Some rivals may have been winning at the company's expense.
AvroBio shares continued their run on Wednesday, despite the firm announcing that it would be conducting a secondary offering.
Inovio Pharma shares dipped on Wednesday after the company said that it was taking measures to cut costs and its overall burn rate. When a company says it’s cutting costs one thing it can mean is...
Johnson & Johnson retreated though it reported better than expected second-quarter before the markets opened on Tuesday.
Gilead and Galapagos each saw shares shoot up on Monday after the companies announced a new collaboration.
Johnson & Johnson is scheduled to report its most recent quarterly results before the markets open on Tuesday.
Capricor Therapeutics shares more than doubled on Monday after the firm announced interim analysis for its Duchenne muscular dystrophy midstage trial.
Alkermes shares made a handy gain on Monday after the firm announced that it would be expanding its New Drug Application for ALKS 3831 to encompass the treatment of bipolar I disorder in addition to...
Illumina shares dropped on Friday after the firm announced a preliminary revenue miss and a 50% cut to its 2019 revenue growth guidance. As a result, a few analysts were quick to weigh in on the...
Leading health care data and analytics technology and services provider Health Catalyst aims to price 6 million shares for an initial public offering is valued up to more than $158 million.
Hookipa Pharma is not a household name, or even well-known within the biotech industry, but it is making waves on Friday after the firm announced an update from the FDA.
The June 28 short interest data have been compared with the previous figures, and short interest in most of these selected marijuana stocks increased.